BioNTech SE (BNTX)

Market Cap	20.73B
Revenue (ttm)	4.24B
Net Income (ttm)	1.03B
Shares Out	237.73M
EPS (ttm)	4.10
PE Ratio	21.15
Forward PE	7.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	348,295
Open	87.40
Previous Close	86.71
Day's Range	86.71 - 88.32
52-Week Range	85.21 - 125.83
Beta	0.23
Analysts	Buy
Price Target	127.58 (+46.29%)
Earnings Date	May 6, 2024

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2019
• Employees: 6,133
• Stock Exchange: NASDAQ
• Ticker Symbol: BNTX

Financial Performance

In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.

Financial numbers in EUR

Analyst Forecast

According to 12 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $127.58, which is an increase of 46.29% from the latest price.

Price Target

$127.58

(46.29% upside)

Analyst Consensus: Buy